Literature DB >> 24191936

Antibody-dependent enhancement and the risk of HIV infection.

Andrea Gorlani1, Donald N Forthal.   

Abstract

Antibody-dependent enhancement (ADE) of infection has been described for a number of viruses including HIV-1. However, the biological role of ADE in HIV disease pathogenesis or in increasing the risk of infection upon exposure is uncertain. In this review, we outline the mechanisms of ADE, as ascertained in vitro. We also discuss several recent human and non-human primate studies that raise concern about ADE resulting from vaccine-induced or passively infused antibodies. Although biologically plausible, an important role for ADE in natural HIV infection has not been directly confirmed. Nonetheless, there is a need for further studies to pinpoint the exact mechanism or mechanisms at play in vivo and, more importantly, to develop assays that can predict the likelihood that a vaccine or antibody infusion will lead to enhanced infection or pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24191936     DOI: 10.2174/1570162x113116660062

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  19 in total

1.  Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge.

Authors:  Sandeep Gupta; Poonam Pegu; David J Venzon; Johannes S Gach; Zhong-Min Ma; Gary Landucci; Christopher J Miller; Genoveffa Franchini; Donald N Forthal
Journal:  J Infect Dis       Date:  2014-05-21       Impact factor: 5.226

Review 2.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

3.  Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251.

Authors:  Johannes S Gach; David Venzon; Monica Vaccari; Brandon F Keele; Genoveffa Franchini; Donald N Forthal
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

4.  An SAMT-247 Microbicide Provides Potent Protection against Intravaginal Simian Immunodeficiency Virus Infection of Rhesus Macaques, whereas an Added Vaccine Component Elicits Mixed Outcomes.

Authors:  Sabrina Helmold Hait; Christopher James Hogge; Mohammad Arif Rahman; Eun-Ju Ko; Ruth Hunegnaw; Zuena Mushtaq; Gospel Enyindah-Asonye; Tanya Hoang; Lisa M Miller Jenkins; Ettore Appella; Daniel H Appella; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2020-05-11       Impact factor: 5.422

5.  Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.

Authors:  Shuying S Li; Peter B Gilbert; Lindsay N Carpp; Chul-Woo Pyo; Holly Janes; Youyi Fong; Xiaoying Shen; Scott D Neidich; Derrick Goodman; Allan deCamp; Kristen W Cohen; Guido Ferrari; Scott M Hammer; Magdalena E Sobieszczyk; Mark J Mulligan; Susan P Buchbinder; Michael C Keefer; Edwin DeJesus; Richard M Novak; Ian Frank; M Juliana McElrath; Georgia D Tomaras; Daniel E Geraghty; Xinxia Peng
Journal:  J Virol       Date:  2019-10-15       Impact factor: 6.549

6.  Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice.

Authors:  Hui Zhao; Hao-Yang Li; Jian-Feng Han; Yong-Qiang Deng; Shun-Ya Zhu; Xiao-Feng Li; Hui-Qin Yang; Yue-Xiang Li; Yu Zhang; E-De Qin; Rong Chen; Cheng-Feng Qin
Journal:  Sci Rep       Date:  2015-01-19       Impact factor: 4.379

7.  Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users.

Authors:  Sarah Sterrett; Gerald H Learn; Paul T Edlefsen; Barton F Haynes; Beatrice H Hahn; George M Shaw; Katharine J Bar
Journal:  Open Forum Infect Dis       Date:  2014-08-14       Impact factor: 3.835

Review 8.  Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies.

Authors:  Sebastian P Fuchs; Ronald C Desrosiers
Journal:  Mol Ther Methods Clin Dev       Date:  2016-11-16       Impact factor: 6.698

Review 9.  Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

10.  A Bistable Switch in Virus Dynamics Can Explain the Differences in Disease Outcome Following SIV Infections in Rhesus Macaques.

Authors:  Stanca M Ciupe; Christopher J Miller; Jonathan E Forde
Journal:  Front Microbiol       Date:  2018-06-06       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.